<DOC>
	<DOC>NCT00097929</DOC>
	<brief_summary>A study to determine the safety, tolerability, and anti-tumor effectiveness of an oral investigational drug in the treatment of relapsed diffuse large B-cell lymphoma.</brief_summary>
	<brief_title>An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patient must be 18 years or older with relapsed Diffuse Large Bcell Lymphoma (DLBCL). Stable disease or better for at least 3 months on most recent treatment Have not received any chemotherapy, radiation therapy, major surgery, or any other investigational therapy for at least 4 weeks prior to entry in this study Adequate blood testing, liver, and kidney function as required by the study. Eligible subjects will allow tissue samples to be examined and stored. Patient has been treated with other investigational agents with a similar antitumor mechanism. Patient should not have failed more than 3 prior treatment regimens.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Relapsed Diffuse Large B-cell Lymphoma</keyword>
</DOC>